Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
CE Teunissen, IMW Verberk, EH Thijssen… - The Lancet …, 2022 - thelancet.com
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …
recent results have shown that they could become a reality. Convincing data generated with …
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration
Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …
Advances in the development of new biomarkers for Alzheimer's disease
TO Klyucherev, P Olszewski, AA Shalimova… - Translational …, 2022 - Springer
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …
Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders
Importance There are limitations in current diagnostic testing approaches for Alzheimer
disease (AD). Objective To examine plasma tau phosphorylated at threonine 217 (P-tau217) …
disease (AD). Objective To examine plasma tau phosphorylated at threonine 217 (P-tau217) …
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
With the potential development of new disease-modifying Alzheimer's disease (AD)
therapies, simple, widely available screening tests are needed to identify which individuals …
therapies, simple, widely available screening tests are needed to identify which individuals …
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease
Highly sensitive and specific plasma biomarkers for Alzheimer's disease (AD) have the
potential to improve diagnostic accuracy in the clinic and facilitate research studies including …
potential to improve diagnostic accuracy in the clinic and facilitate research studies including …
Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
The neuropathological confirmation of amyloid-β (Aβ) plaques and tau neurofibrillary
tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer's disease …
tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer's disease …
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
Introduction This study investigated the diagnostic and disease‐monitoring potential of
plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) …
plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) …